Prof. Nagi S. El Saghir, MD from the American University of Beirut Medical Center, Beirut, Lebanon is commenting on the abstract 386TiP - Ribociclib plus Goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer - RIGHT Choice study
Conleth Murphy, MD, PhD from the Bon Secours Cork Cancer Centre, Cork, Ireland is commenting on the abstract LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
Prof. Mario Campone, MD from the Institut de Canceérologie de L’Ouest, Saint Herblain, France is commenting on the abstract Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial
Noam Falbel Pondé, MD, PhD from the A.C.Camargo Cancer Center, São Paulo, Brazil is commenting on the abstract 385TiP - RIBOB : A Study on the efficacy and safety of Ribociclib in combination with letrozole in Older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced Breast cancer (aBC) with no prior systemic therapy for advanced disease
